Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Barry Borlaug Added: 7 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT… View more
Author(s): Harriette Van Spall , Tauben Averbuch Added: 1 year ago
HFA 2024 — Dr Tauben Averbuch and Dr Harriette Van Spall (McMaster University, Hamilton, CA) discuss the findings from the PACT-HF trial. In this analysis of PACT-HF, investigators looked at long term sex-specific clinical outcomes and healthcare resource utilisation following hospitalisation for heart failure at 5 years.Findings shows that clinical outcomes and overall costs were similar between… View more
Author(s): Muthiah Vaduganathan Added: 1 year ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more
Author(s): Nir Uriel Added: 7 months ago
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Society of America's annual congress, HFSA 2025.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators. View more
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more
Research Area(s) / Expertise: Job title: Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is an internationally recognised interventional cardiologist and clinical researcher based in New York, United States. She has spent much of her professional career at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, where she has become a leading figure in cardiovascular clinical trials, interventional cardiology, and outcomes research. Her work is widely noted… View more
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted… View more